ICYMI: Combination ixekizumab (Taltz) + tirzepatide (Zepbound) outperformed ixekizumab monotherapy in adults with moderate-to-severe plaque psoriasis and overweight/obesity. Details:

New pediatric HAE guideline recommends oral sebetralstat (Ekterly) as first-line on-demand therapy for adolescents ≥12 yrs. Early, self-administered treatment emphasized to improve outcomes. #HAE #Pediatrics

On the latest episode of Diabetes Dialogue, cohosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss the Portal implantable insulin pump, which was just granted Breakthrough Designation by the FDA. Watch now:

Advancing care for biliary atresia is a priority — and it starts with better prognostic tools. Hear from Ahmad Anouti, MD, about why early recognition, direct bilirubin testing, and emerging serum biomarkers may help predict long-term outcomes more effectively. Watch now:

Beyond PASI & BSA: Ronald Vender, MD, discusses why patient-reported outcomes — itch, pain, scaling & quality of life — matter when choosing biologics for psoriasis. Details:

COMP360 psilocybin shows next-day onset in #TRD. In phase 3 trial, 2 doses (25 mg) achieved a –3.8 MADRS difference at week 6, with sustained 26-week response. Insights from Steve Levine, MD, @COMPASSPathway, here:

On February 19, the AHA and ACC released a joint clinical guideline for the diagnosis, treatment, and managment of pulmonary embolism, detailing risk factors, treatment strategies, and postoperative follow-up plans. Read more: www.hcplive.com/view...

1 year ago, semaglutide (Ozempic) earned FDA approval for CKD in T2D — the first GLP-1 RA to reduce risk of kidney failure & CV death in this population. HCPLive revisits the impact with experts from Cleveland Clinic, the AHA & Holly Kramer, MD. Read more: www.hcplive.com/view...

Ronald Vender, MD, highlights the real-world relevance of BE RADIANT — showing durable patient-reported improvements with bimekizumab through 3 years in plaque psoriasis.🔍 More:

Phase 2a trial shows 10-min IV DMT (SPL026) significantly reduces #MDD symptoms vs placebo. Proof-of-concept supports short-acting psychedelics in #depression. #Psychiatry

We spoke with Justin Ezekowitz, MD, to discuss his recent analysis of the SODIUM-HF trial, which indicated that dietary salt limitations may only benefit patients at the lowest risk for heart failure, contrary to popular belief. Watch now:

An estimated 90% of US adults fall along the cardiovascular-kidney-metabolic spectrum. Experts say new therapies, including GLP-1 receptor agonists for CKD, are changing how overlapping risk is managed. Read more:

ICYMI: @YolTech Therapeutics announced positive interim data from an investigator-initiated trial of YOLT-202, the Company’s investigational in vivo base editing therapy, for the treatment of alpha-1 antitrypsin deficiency. Learn more: www.hcplive.com/view...

New 3-year BE RADIANT data suggest bimekizumab improved symptoms and quality of life in plaque psoriasis — with benefits seen as early as 4 weeks.💡 More: www.hcplive.com/view...

COMP360 met the primary endpoint in its second phase 3 TRD trial (COMP006), with a significant change in MADRS scores from baseline to week 6. Findings reinforce COMP360’s potential for #TRD.

In an interview with Nina Ajmone Marsan, MD, and Pilar Lopez Santi, MD, we discussed the importance of including female patients in clinical research for aortic regurgitation. Watch now:

Dual costimulation with belatacept + dazodalibep targets complementary immune pathways, offering a CNI-free approach to kidney transplant immunosuppression. #KidneyTransplant #Immunology #TransplantMedicine Watch full interview with Allan Kirk, MD, PhD here:

Hear from Alan Buchman, MD, MSPH, about his research showing limited uptake of short bowel syndrome-specific ICD-10 codes, raising concerns about misclassification and the true burden of disease. 🔗

Treating psoriasis and obesity together may improve outcomes.💡 Combination ixekizumab (Taltz) + tirzepatide (Zepbound) outperformed ixekizumab monotherapy in adults with moderate-to-severe plaque psoriasis and overweight/obesity. Details: www.hcplive.com/view...

New international pediatric #HAE guidance recommends oral sebetralstat as first-line on-demand therapy for adolescents ≥12. Emphasis: early treatment & self-administration. www.hcplive.com/view...#HAE#allergy

Data from the recent CORALreef Lipids phase 3 trial of enlicitide suggests remarkably high treatment adherence. In an interview, Ann Marie Navar, MD, PhD, attributes this to a habit-forming dosing regimen. Watch now:

As conversations from #NationalDonorDay continue, experts examine why kidney transplantation remains the treatment of choice for kidney failure and how innovation is shaping outcomes for recipients and donors alike.

What’s next in dermatology for 2026? At #MauiDerm Hawaii, leading experts weigh in on emerging oral psoriasis therapies, next-gen biologics, AI in oncology, acne innovation, CSU advances, and more. Read more: www.hcplive.com/view...#MauiDerm #Dermatology #Psoriasis #AtopicDermatitis #CSU

In this segment from the latest episode of Diabetes Dialogue, cohosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss the controversy surrounding Hims & Hers, who have been sued by Novo Nordisk for their "knock-off" oral GLP-1s. Watch now:

MAJESTY, the first global phase 3 study in primary membranous nephropathy (PMN), met its primary endpoint of complete remission at 2 years with obinutuzumab (Gazyva).​​ Read here: www.hcplive.com/view...

Abrahem Kazemi, MD, discusses access gaps, skin of color care, and the future of alopecia & HS treatment in the latest episode of the Skin of Color Savvy podcast.🎙️ Listen here:

Study shows that a user-friendly calculator can predict a 6-year lung cancer risk in 2 to 3 minutes. As Jessica Moffatt, PhD, says in an interview, the tool has safeguards in place: www.hcplive.com/view... #LungCancer

In the latest episode of DIabetes Dialogue, cohosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, break down the recent lawsuit from Novo Nordisk against Hims, reacting to their undisclosed, compounded formulation of oral Ozempic. Watch now:

As we end Heart Failure Awareness Week 2026, take some time to learn where we can help to spread awareness about this debilitating disease - and the plethora of treatments and interventions that can prevent it from upending patients' lives. Watch now:

Seasonal birch pollen exposure recalls IgE⁺ plasmablasts, boosting #IgE without IgG. Rudolf Valenta says this challenges class-switch models in humans.

In the latest episode of Diabetes Dialogue, cohosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss the risks of relying on cheaper, compounded formulations of oral Ozempic for weight loss. Watch now: www.hcplive.com/view...

A pilot phase trial of a wearable patch for continuous drug concentration measurement captured vancomycin levels in 5-minute intervals, which study investigator, Sophie Stocker, PhD, BsC, discusses in an interview. Watch here:

New data reported seasonal #IgE boosts are driven by IgE⁺ plasmablasts, not memory B cells. In this Q&A, Maria Byazrova & Rudolf Valenta explain how basophils are reloaded during exposure. www.hcplive.com/view...#IgE#allergy

The flu has long been associated with severe cardiac events. In an interview with Jeffrey Downey, PhD, from Mount Sinai, we discuss the study that pinpointed the process at fault. Watch now: interferon-1-responsible-for-causing-cardiac-events-during-influenza-infection-with-jeffrey-downey-phd

The American Society of Hematology released new 2026 Guidelines for Management of Relapsed/Refractory Acute Lymphoblastic Leukemia in Adolescents and Young Adults. Read more:

ICYMI: BridgeBio Pharma announced positive topline results from PROPEL 3, a phase 3 study of oral infigratinib in children with achondroplasia, showing it met the primary endpoint of change from baseline in annualized height velocity at week 52. Read now:

At #MauiDerm2026, Ashfaq Marghoob, MD, emphasized reassurance in pediatric dermoscopy—highlighting benign scalp, palm/sole, and nail patterns in children. He also shared optimism about AI improving melanoma screening. Watch/read more:

Catch this clip of David Golden, MD, @JohnsHopkinsSPH,on how COVID-19 influenced #anaphylaxis guidance, prioritizing at-home #epinephrine over automatic ER visits. Watch the full special report here:

A recent study has indicated that focusing on food quality may provide better cardiometabolic benefits than focusing on low carbs or low fat. We spoke with Zhiyuan Wu, PhD, lead investigator for the study, to discuss why. Watch now:

In phase 2 VALIANT, verekitug reduced the average annual rate of asthma flare-ups in those with severe asthma, with positive topline results announced by Upstream Bio. Read here: www.hcplive.com/view...

At #MauiDerm2026, Ashfaq Marghoob, MD, shared key dermoscopy pearls for special sites—face, palms, soles, and nails—highlighting microanatomy differences that shape melanoma detection. Read more:

We spoke with Adam Bress, PharmD, MS, of the University of Utah School of Medicine, to discuss his recent findings regarding the Apple Watch's hypertension notification program - and its potential for false negatives. Watch now:

An interview with study investigator Frank Gonzalez from the Children’s Hospital of Los Angeles suggests severe cold temperatures are independently associated with an increased risk of pain crisis in pediatric patients with sickle cell disease. Watch here:

ICYMI: Hengrui Pharma and Kailera Therapeutics announced positive topline data from a phase 2 clinical trial of once-daily oral ribupatide, a GLP-1/GIP receptor dual agonist peptide, in adults living with obesity in China. Read more: www.hcplive.com/view...

Positive 52-week REZOLVE-AD data show rezpegaldesleukin, a novel Treg biologic, delivered durable improvements in moderate-to-severe atopic dermatitis with monthly or quarterly dosing.💡 #AtopicDermatitis www.hcplive.com/view...

#FDA accepts NDA & grants Priority Review for Takeda’s oveporexton (TAK-861) for #narcolepsy type 1. Phase 3 trials show near-normal wakefulness. PDUFA target: Q3 2026. www.hcplive.com/view...#FDA

A recent study has shown that 8 in 10 adults in the US with hypertension have uncontrolled high blood pressure, despite having access to healthcare and being within 10 mmHg of AHA/ACC guidelines. We spoke with Shakia Hardy, PhD, MPH, to learn more. Read the Q&A here: www.hcplive.com/view...

Ongoing evidence continues to link inflammation with CKD progression. FLOW trial, investigator Vlado Perkovic, noted that semaglutide lowered CRP by ~40% and slowed kidney decline, reinforcing inflammation as a target in CKD care. Learn more:

Updated international #urticaria guidelines (Dec 2024) keep the stepwise algorithm but clarify where evidence has evolved (biomarkers, provocation testing, pediatric care, & emerging therapies):

New phase 3 data show Ameluz PDT met its primary endpoint and was highly statistically superior to vehicle in treating mild-to-moderate actinic keratosis on the extremities, neck, and trunk.💡 #Dermatology www.hcplive.com/view...